Vaccine Manufacture and Supply – News and Features

Technology Networks spoke with UNICEF about the challenges in achieving vaccine equality, what factors contribute to low immunization rates, how we can work to make vaccines available to marginalized communities and the consequences of vaccine inequality.

Sachin Rawat explores the concept of vaccine booster shots, how they are manufactured and when their administration is appropriate, with insights from experts in immunology.

A peer-reviewed analysis of US national survey data of 75,000 adults shows, from early January to late March, a near “18 percentage point” increase of adults who have either had the COVID-19 vaccine jab or are willing to do have it.

The UK and Australia will share COVID-19 vaccine doses to benefit each other’s life-saving vaccine rollout programs.

The FDA has approved the first COVID-19 vaccine. The vaccine (once known as the Pfizer-BioNTech COVID-19 Vaccine) will now be marketed as Comirnaty, for the prevention of disease in individuals 16 years of age and older.

This article covers the challenges associated with conventional vaccine approaches and elaborates on some of the recent innovations which can help design better vaccines.

Severe acute respiratory syndrome coronavirus-2, the causal agent of the ongoing coronavirus pandemic, has been evolving ever since the first outbreak in December 2019. Researchers believe that rapid vaccination is the most effective strategy to contain the pandemic.

Technology Networks is committed to keeping you updated with the latest research in this space. Here, you'll find a curation of our latest COVID-19 vaccine-related content.

Technology Networks spoke to Hiroshi Kiyono, DDS, PhD, from the Institute of Medical Science at the University of Tokyo who is currently also affiliated with Chiba University and University of California, San Diego, to find out more about MucoRice-CTB, a room-temperature stable oral vaccine being developed using genetically modified rice plants.

A study has shown that total antibody levels appear to start declining from as early as six weeks after complete vaccination and can reduce by more than 50% over 10 weeks.